Gemopatrilat

Gemopatrilat
Clinical data
Other names	BMS-189921
ATC code	None;
Identifiers
	IUPAC name (6S)-Hexahydro-6-[(αS)-α-mercaptohydrocinnamido]-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid;
CAS Number	160135-92-2;
PubChem CID	9886079;
ChemSpider	8061752;
UNII	MU9089C77W;
KEGG	D04312;
ChEMBL	ChEMBL107747;
CompTox Dashboard (EPA)	DTXSID901029484 ;
Chemical and physical data
Formula	C19H26N2O4S
Molar mass	378.49 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1(CCC[C@@H](C(=O)N1CC(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)S)C;
	InChI InChI=1S/C19H26N2O4S/c1-19(2)10-6-9-14(18(25)21(19)12-16(22)23)20-17(24)15(26)11-13-7-4-3-5-8-13/h3-5,7-8,14-15,26H,6,9-12H2,1-2H3,(H,20,24)(H,22,23)/t14-,15-/m0/s1; Key:YRSVDSQRGBYVIY-GJZGRUSLSA-N;

Other namesBMS-189921

Gemopatrilat (INN)^[1] is an experimental drug that was never marketed.^[2] It acts as a vasopeptidase inhibitor.^[3]^[4] It inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase (neprilysin).^[5]

v t e Antihypertensive drugs acting on the renin–angiotensin system (C09)
ACE inhibitors ("-pril")	Sulfhydryl-containing: Captopril Rentiapril Zofenopril (+nebivolol) Dicarboxylate-containing: Enalapril^# (+lercanidipine, +nitrendipine) Benazepril (+amlodipine, +pimobendan) Cilazapril Delapril (+manidipine) Imidapril Lisinopril (+amlodipine, +HCT) Moexipril Perindopril (+amlodipine, +bisoprolol, +indapamide, +amlodipine and indapamide, +bisoprolol and amlodipine, +bisoprolol, amlodipine, and indapamide) Quinapril (+HCT) Ramipril (+amlodipine, +amlodipine and HCT, +bisoprolol, +felodipine) Spirapril Temocapril Trandolapril (+verapamil) Phosphonate-containing: Ceronapril Fosinopril (+HCT) Other/ungrouped: Alacepril
AIIRAs ("-sartan")	Azilsartan Candesartan (+amlodipine, +amlodipine and HCT) Eprosartan Fimasartan Irbesartan (+amlodipine, +amlodipine and HCT, +HCT) Losartan (+amlodipine, +HCT) Olmesartan (+amlodipine, +amlodipine and HCT, +HCT) Tasosartan^§ Telmisartan (+amlodipine, +amlodipine and HCT, +amlodipine and indapamide, +HCT) Valsartan (+aliskiren, +amlodipine, +amlodipine and HCT, +HCT, +lercanidipine, +nebivolol, +sacubitril)
Renin inhibitors ("-kiren")	Aliskiren (+amlodipine, +HCT, +amlodipine and HCT) Remikiren^§
Dual ACE/NEP inhibitors	Gemopatrilat Ilepatril Omapatrilat Sampatrilat
Neprilysin inhibitors	Sacubitril (+valsartan)
Other	Sparsentan
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

Related Articles